Licensing opportunity - Pasteur DI number: 2004-101
Polypeptides of Leishmania major vaccinal, therapeutical and diagnostic applications thereof

DESCRIPTION of INVENTION

The invention relates to new proteins: excreted/secreted polypeptides of Leishmania major and polynucleotide encoding same that provides an immune response and/or a protective immunity to mammals against a Leishmania major strain. The invention also concerns a method for the diagnosis of a Leishmaniasis

POTENTIAL APPLICATION

- Pharmaceutical compositions, vaccines and methods for providing an immune response and/or a protective immunity to mammals against a *Leishmania major* strain
- Drug targets.
- Leishmaniasis diagnostic kit.
- Application in mammals, included humans.

SPECIFIC ADVANTAGE

These new secreted/excreted polypeptides identified as defined in the invention finds a particular use as drug target for identifying a molecule capable of preventing a Leishmaniasis.

PATENT STATUS

Published - WO2006108720 (*Polypeptides of Leishmania Major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof*).
National phases: EP1869073 (B1) delivered on 17/08/2011 / US7888492 (B2) delivered on 15/02/2011 / MX299358 delivered on 18/05/2012

RELATED PUBLICATION

Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites.
Chenik M, Lakhal S, Ben Khalef N, Zribi L, Louzir H, Dellagi K.
Parasitology. 2006 Apr;132(Pt 4):493-509. Epub 2006 Jan 3.

Selection of endogenous reference genes for gene expression analysis in Leishmania major developmental stages.
Ouakad M, Bahi-Jaber N, Chenik M, Dellagi K, Louzir H.
Parasitol Res. 2007 Jul;101(2):473-7. Epub 2007 Feb 23.

A High-Throughput Turbidometric Assay for Screening Inhibitors of Leishmania major Protein Disulfide Isomerase. Khalaf NB, De Muylder G, Ratnam J, Kean-Hooi Ang K, Arkin M, McKerrow J, Chenik M
J Biomol Screen. 2011 Jun;16(5):545-51. Epub 2011 Mar 25.

INVENTORS:

Mehdi CHENIK
Hechmi LOUZIR
Koussay DELLAGI
Sami LAKHAL

Laboratory: Immunopathology, vaccinology and molecular genetics LR00SP06, a Institut Pasteur de Tunis laboratory, in Tunis, Tunisia

"We are working around a main topic that is based on the host-pathogenic interaction. We are doing epidemiological studies in order to better understand the disease history, characterizing parasite virulence factors, doing vaccinology's studies on Leishmaniasis and developing diagnostic tools".

Commercial Status
Exclusive or non exclusive licenses and collaborative research

Keywords
leishmaniases, L.major, cellular immune responses, secreted polypeptides

Tech Brief issue date: January 2013

Contact: Mr. Oussama BEN FADHEL, Project Manager in Technology Transfer
Institut Pasteur de Tunis – 13 place Pasteur– 1002 Tunis, TUNISIE
Tel: (+216) 71.845 415 - Fax: (+216) 71 791 833 – email: oussama.benfadhel@pasteur.rns.tn